Compare Amgen, Inc. (AMGN) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs AngloGold Ashanti Limited — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while AngloGold Ashanti Limited trades at $80.65 (market cap $41.51B). The key difference: Amgen, Inc. is far larger — about 4.7× AngloGold Ashanti Limited's market cap, and AngloGold Ashanti Limited pays the higher dividend (5.6%). Which is the better fit depends on your goals.
| AMGN | AU | |
|---|---|---|
Market Cap | $196.12B | $41.51B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $128.26 |
52-Week Low | $271.18 | $46.25 |
Enterprise Value | $241.41B | $40.64B |
Dividend Yield | 2.77% | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
AngloGold Ashanti (AU) trades at $82.10, up 0.23% on the day, with a bearish technical signal but strong fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $2.52 versus $2.27 forecast. The company shows robust revenue growth, with 2025 revenue at $9.89 billion and net income margin of 26.64%. A proposed share repurchase program and a $1.16 dividend for H1 2026 highlight capital returns. Analyst consensus is bullish with a $116.25 price target, though technical indicators suggest near-term resistance.
Outlook remains positive driven by gold price strength and operational efficiency, but risks include geopolitical exposure and commodity volatility. The stock offers value with a P/E of 12.06 and high ROE of 45.39%, yet bearish technical trends and recent earnings misses in Q3 and Q4 2025 warrant caution. Institutional sentiment is mixed, with 64% buy ratings but technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
